BackgroundCheck.run
Search For

Paul D Rennert, 67205 Underwood St, Holliston, MA 01746

Related to:
Vincent P Rennert 96

Paul Rennert Phones & Addresses

205 Underwood St, Holliston, MA 01746    508-4299587   

Newtonville, MA   

Truro, MA   

278 Ridge St, Millis, MA 02054    508-3768243   

Roxbury, MA   

Get Report
Control this profile

Mentions for Paul D Rennert

Paul Rennert resumes & CV records

Resumes

Paul Rennert Photo 20

Principal Scientist At Biogen Idec

Location:
Greater Boston Area
Industry:
Biotechnology
Paul Rennert Photo 21

President And Chief Strategy Officer

Location:
205 Underwood St, Holliston, MA 01746
Industry:
Biotechnology
Work:
X-Rx Discovery - Waltham, MA since Mar 2013
Chief Scientific Officer X-Rx Discovery - Waltham, MA since Jan 2013
Executive Consultant Clarion Bio May 2012 - Mar 2013
Principal Biogen Idec May 1995 - May 2012
Principal Scientist Repligen Inc 1986 - 1995
various
Education:
University of Vermont 1982 - 1986
Colby College 1975 - 1980
Skills:
Immunology, Drug Development, Biotechnology, Assay Development, Drug Discovery, In Vitro, Clinical Development, Pharmacology, In Vivo, Biopharmaceuticals, Inflammation, Monoclonal Antibodies, Protein Chemistry, Oncology, Lifesciences, Cell, Biologics, Small Molecules, Cardiovascular Disease, Ind, Technology Transfer, Biochemistry, Cell Biology, Due Diligence, Asthma, Antibodies, Rheumatology, Validation, Translational Research, Clinical Trials, Autoimmunity, Cancer, Technology Evaluation, Stem Cells, Rheumatoid Arthritis, Business Development, Autoimmune Diseases, Translational Medicine, Biomarkers, Immunoassays, R&D, Toxicology, Clinical Research, Biomarker Discovery, Lead Change, Metabolism, Elisa, Signal Transduction, High Throughput Screening, Lupus

Publications & IP owners

Us Patents

Methods For Inducing A Population Of T Cells To Proliferate Using Agents Which Recognize Tcr/Cd3 And Ligands Which Stimulate An Accessory Molecule On The Surface Of The T Cells

US Patent:
6352694, Mar 5, 2002
Filed:
Mar 10, 1995
Appl. No.:
08/403253
Inventors:
Carl H. June - Rockville MD
Craig B. Thompson - Chicago IL
Gary J. Nabel - Ann Arbor MI
Gary S. Gray - Brookline MA
Paul D. Rennert - Holliston MA
Assignee:
Genetics Institute, Inc. - Cambridge MA
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 3514
US Classification:
424 9371, 424 937, 424534, 424577, 424578, 435 2, 435375, 435377
Abstract:
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

Ctla4-C4 Fusion Proteins

US Patent:
6444792, Sep 3, 2002
Filed:
Jan 8, 1999
Appl. No.:
09/227595
Inventors:
Gary S. Gray - Brookline MA
Jerry Carson - Belmont MA
Kashi Javaherian - Lexington MA
Paul D. Rennert - Holliston MA
Sandra Silver - Boston MA
Assignee:
Repligen Corporation - Needham MA
International Classification:
A61K 39395
US Classification:
5303873, 5303871, 4241341
Abstract:
CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e. g. , B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e. g. , CD28 and/or CTLA4) on the surface of T cells to thereby suppress an immune response in the subject, for example to inhibit transplantation rejection, graft versus host disease or autoimmune responses.

Methods For Selectively Stimulating Proliferation Of T Cells

US Patent:
6534055, Mar 18, 2003
Filed:
May 4, 1995
Appl. No.:
08/435816
Inventors:
Carl H. June - Rockville MD
Craig B. Thompson - Chicago IL
Gary J. Nabel - Ann Arbor MI
Gary S. Gray - Brookline MA
Paul D. Rennert - Holliston MA
Assignee:
Genetics Institute, Inc. - Cambridge MA
International Classification:
A61K 3514
US Classification:
424 9371, 424 937, 424534, 424577, 424578, 435 2, 435375, 435377
Abstract:
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

Methods Of Inhibiting T Cell Proliferation Or Il-2 Accumulation With Ctla4- Specific Antibodies

US Patent:
6719972, Apr 13, 2004
Filed:
Jun 3, 1994
Appl. No.:
08/253783
Inventors:
John G. Gribben - Brookline MA
Gordon J. Freeman - Brookline MA
Lee M. Nadler - Newton MA
Paul Rennert - Holliston MA
Cindy L. Jellis - Londonderry NH
Edward Greenfield - Randolph MA
Gary S. Gray - Brookline MA
Assignee:
Repligen Corporation - Cambridge MA
Dana-Farber Cancer Institute - Boston MA
International Classification:
A61K 39395
US Classification:
4241541, 4241301, 4241331, 4241341, 4241391, 4241411, 4241431, 4241441, 4241451, 4241531, 4241731, 5303871, 5303873, 5303879, 5303881, 5303882, 53038822, 5303887, 53038873, 53038875
Abstract:
Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an epitope of CTLA4 distinct from the binding sites of B7-1 and B7-2. Upon binding of the antibody to CTLA4 on an activated T cell, in the presence of an antigenic signal, antigen specific apoptosis is induced. The invention also describes a novel natural CTLA4 ligand, distinct from B7-1 and B7-2, which mediates induction of apoptosis. Pharmaceutical compositions of anti-CTLA4 antibodies or other isolated CTLA4 ligands which can be administered to subjects to induce T cell apoptosis, thereby clonally deleting antigen specific. T cells, such as alloreactive T cells in transplantation situations or autoreactive T cells in autoimmune disorders, are also disclosed. Methods for inducing T cell apoptosis in vitro with an anti-CTLA4 antibody or other ligand of the invention together with an antigen specific signal are also disclosed, e. g.

Ctla4-Immunoglobulin Fusion Proteins Having Modified Effector Functions And Uses Therefor

US Patent:
6750334, Jun 15, 2004
Filed:
Feb 2, 1996
Appl. No.:
08/595590
Inventors:
Gary S. Gray - Brookline MA
Jerry Carson - Belmont MA
Kashi Javaherian - Lexington MA
Cindy L. Jellis - Londonderry NH
Paul D. Rennert - Holliston MA
Sandra Silver - Boston MA
Assignee:
Repligen Corporation - Newton MA
International Classification:
C07H 2104
US Classification:
536 234, 530350, 5303873
Abstract:
CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e. g. , B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e. g. , CD28 and/or CTLA4) on the surface of T cells to thereby suppress an immune response in the subject, for example to inhibit transplantation rejection, graft versus host disease or autoimmune responses.

Heterologous Polypeptide Of The Tnf Family

US Patent:
6875846, Apr 5, 2005
Filed:
Aug 7, 2002
Appl. No.:
10/214065
Inventors:
Paul Rennert - Millis MA, US
Jeffrey S. Thompson - Stoneham MA, US
Christine Ambrose - Reading MA, US
Teresa G. Cachero - Brookline MA, US
Assignee:
Biogen Idec MA Inc. - Cambridge MA
International Classification:
C07K014/52
C07H021/04
US Classification:
530351, 536 235
Abstract:
A newly identified heteromeric ligand of the Tumor Necrosis Factor (TNF)-family, referred to hereinafter as “APBF” has been identified.

Methods For Selectively Stimulating Proliferation Of T Cells

US Patent:
6887466, May 3, 2005
Filed:
Jul 8, 1999
Appl. No.:
09/350202
Inventors:
Carl H. June - Rockville MD, US
Craig B. Thompson - Chicago IL, US
Gary J. Nabel - Ann Arbor MI, US
Gary S. Gray - Brookline MA, US
Paul D. Rennert - Holliston MA, US
Assignee:
Genetics Institute, Inc. - Cambridge MA
Regents of the University of Michigan - Ann Arbor MI
The United States of America as represented by the Secretary of the Navy - Washington DC
International Classification:
A61K035/14
A61K035/26
A61K035/28
US Classification:
424 9371, 4241301, 4241411, 4241431, 4241441, 4241531, 4241541, 4241731, 424 937, 424534, 424577, 424578, 435 2, 435 71, 435 721, 435 724, 435375, 435377, 5303871, 5303881, 5303882, 53038822, 5303887, 53038873, 53038875
Abstract:
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

Methods Of Treating Hiv Infected Subjects

US Patent:
6905680, Jun 14, 2005
Filed:
Jan 26, 1996
Appl. No.:
08/592711
Inventors:
Carl H. June - Rockville MD, US
Craig B. Thompson - Chicago IL, US
Gary J. Nabel - Ann Arbor MI, US
Gary S. Gray - Brookline MA, US
Paul D. Rennert - Holliston MA, US
Assignee:
Genetics Institute, Inc. - Cambridge MA
Regents of the University of Michigan - Ann Arbor MI
The United States of America as represented by the Secretary of the Navy - Washington DC
International Classification:
A61K035/14
A61K035/26
A61K035/28
US Classification:
424 9371, 4241301, 4241411, 4241431, 4241441, 4241531, 4241541, 4241731, 424 937, 424534, 424577, 424578, 435 2, 435 71, 435 721, 435 724, 435375, 435377, 5303871, 5303881, 5303882, 53038822, 5303887, 53038873, 53038875
Abstract:
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

Possible Relatives

Aaron J Rennert  Dara E Rennert  Karen S Rennert  Peter L Rennert  Richard F Rennert  Robert G Rennert  Amy L Rennert  Paul M Johnson  Paul Stamps  Paul B Stanaway 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.